- Home
- MREO vs CLDT Comparison
MREO vs CLDT Comparison
Compare MREO & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | CLDT |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 328.9M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MREO | CLDT |
|---|---|---|
| Price | $0.46 | $7.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $3.90 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 21.9M | 244.5K |
| Earning Date | 11-10-2025 | 02-25-2026 |
| Dividend Yield | N/A | ★ 5.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $500,000.00 | ★ $301,376,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,363.05 | N/A |
| P/E Ratio | ★ N/A | $587.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $5.83 |
| 52 Week High | $3.26 | $8.90 |
Technical Indicators
Market Signals| Indicator | MREO | CLDT |
|---|---|---|
| Relative Strength Index (RSI) | 31.93 | 57.13 |
| Support Level | $0.42 | $6.87 |
| Resistance Level | $0.78 | $7.44 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 10.72 | 57.47 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania among others. Substantially all of the company's assets are held and operated by its Operating Partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. The firm operates through a single segment because of the similar economic characteristics of its hotels. Chatham's revenue streams include Room, Food and beverage, and Other. Room comprises the majority of total revenue. Chatham's hotels operate under brands which include, Hilton, Marriott, and Hyatt.